SARDRICS

Simplifying Progress

Polyplus-Sartorius: A Synergistic Portfolio to be Part of the Antibody Solution.

Recently acquired by Sartorius, Polyplus is now part of the solution in the recombinant antibody production field. From transfection reagents to plasmid design and antibody fragments production, we support customers in improving yield for protein production. In addition, Sartorius has a valuable expertise in cell line development for antibody production, antibody screening and functional characterization.

Younes Boulila, Business Manager EMEA - younes.boulila@sartorius.com; Philippe Ledent, Chief Scientific Officer - ph.ledent@xpress-biologics.com; Marine Houdou, Plasmid Engineering Specialist - marine.houdou@sartorius.com

FectoPRO

- Cost-effective transient gene expression with lower plasmid DNA amount.
- Compatible with various mammalian expression media and high cell density systems.
- Chemically defined and animal derived component free.




\$ € Ŷ

Α

В

FectoPRO[®] - Amazingly high protein and antibody yields in CHO and HEK 293 cells










- Synergistic association of FectoCHO® CD Expression medium and FectoPRO®, the transfection reagent.
- Outstanding protein production yields in several CHO cells.
- Chemically defined.



FectCHO Expression System to boost antibody yields











FectoPRO® gives superior protein production yields in suspension HEK-293 cells. Cells were seeded at 1 x 10⁶ cells/ml in 30 ml of FreeStyle™ 293 Expression Medium and transfected with FectoPRO® + FectoPRO® Booster (0.4 µg DNA/ml), FreeStyle™ MAX Reagent (1.25 µg DNA/ml) or PElpro® (1 µg DNA/ml) following recommended protocols for the respective reagents. IgG3-Fc (34 kDa) production was assayed 120 h (HEK-293 cells) after transfection by protein G affinity quantification (HPLC).

FectoCHO® Expression system outperforms ExpiCHO™ Expression System in terms of protein production kinetics in ExpiCHO-S cells. ExpiCHO-S[™] cells were either cultivated in FectoCHO® CD Expression Medium and transfected with FectoPRO® reagent following the recommended protocol, or in ExpiCHO™ Expression Medium and transfected following the recommended protocol with ExpiFectamine™ CHO transfection reagent. IgG3-Fc production was assayed over 10 days post-transfection using protein G Biosensors (fortéBIO® BLItz)




MW IN FT F2 F3 PR PNR 200










D.



Quality and yield of production of Trastuzumab monoclonal antibody using the two strategies (A

and B), in ExpiCHO cells. Left. Electrophoretic gels stained with Coomassie Blue. MW: Molecular

Weight; IN: Input, harvest from 7 days of culture prior to Protein A purification; FT: Flow Through;

F2 & F3: elution fraction 2 and 3 as collected with Akta FPLC; PR: pooled positive elution fractions

migrated on gel in reducing conditions; PNR: pooled positive elution fractions migrated on gel in

non reducing condition. Right. ExpiCHO cells were transfected with each plasmid architecture (A

and B), following the routine protocol of an experienced production platform (CERGroup, Liège,

Belgium). Trastuzumab production was measured over 7 days post-transfection using ELISA.

Plasmid design to express the therapeutic Trastuzumab monoclonal antibody built with the e-Zyvec ® technology. A. Two monocistronic plasmids containing each one chain of the antibody (heavy chain (HC) or light chain (LC)). B. Single bicistronic plasmid containing the two chains of the antibody (HC and LC), each expression being driven by a CMV promoter resulting in a dual promotor architecture.

C Plasmi

HC Plasmic

And more...

